ArticleJournal of cellular and molecular medicine2025
Multifaceted Analysis of Lactobacillus plantarum DMR14 Reveals Promising Antidiabetic Properties Through In Vivo Assays and Molecular Simulations.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Due to the growing concern about diabetes worldwide, we investigated the antidiabetic potential of Lactobacillus plantarum DMR14, assessing its effects on the diabetic mice and identifying safe, bioactive compounds targeting DPP4 protein for drug development through various methods, including in vivo assays, GC-MS analysis and molecular docking simulations. The animal experiments showed that after 3 weeks of treatment, the blood sugar levels of mice given the bacteria were reduced by 35.03% compared to baseline. The treatment also significantly lowered blood lipids such as triglycerides, total cholesterol and LDL cholesterol, but did not affect HDL cholesterol levels. Additionally, we identified three compounds that effectively targeted a protein (DPP4) involved in diabetes (PDB ID: 4A5S). These compounds were predicted to be safe for absorption, processing and elimination by the body, and showed no signs of inducing cancer in computer simulations. Further simulations indicated that these compounds bind stably to the protein over time. Diabetic mice treated with Lactobacillus plantarum DMR14 exhibited improved organ health, reduced glucose levels and better metabolic markers. Computer analysis suggested compounds that could enhance enzyme inhibition, indicating potential antidiabetic properties in this strain. These suggested compounds could be considered potential candidates for developing antidiabetic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.